US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Biodesix, Inc. - Common Stock
(NQ:
BDSX
)
7.560
-0.740 (-8.92%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biodesix, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans
April 26, 2021
From
Biodesix, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 26, 2021
Gainers Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 72.91% to $7.47 during Monday's regular session. Reviva Pharmaceuticals's stock is trading at a volume of...
Via
Benzinga
Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021
April 26, 2021
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management
April 22, 2021
From
Biodesix, Inc.
Via
Business Wire
Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patients
April 10, 2021
From
Biodesix, Inc.
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >